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ChemokinesThe present study investigated the effects of the anthraquinone derivative (O,O′-bis-(3′-iodopropyl)-1,4-
dihidroxyanthraquinone — DIPDHAQ), mitoxantrone analog, in an experimental autoimmune encepha-
lomyelitis (EAE) model. The results showed that DIPDHAQ treatment improved the clinical signs of the
disease (n=10; vehicle: 3.8±0.3; DIPDHAQ: 1.4±0.9). The improvement was associated with a decrease
of inﬂammatory cells, demyelination, IL-17, IFN-γ, IL-12p40, IL-6, TGF-β, CCL5 and CCL20 levels in the
spinal cord. DIPDHAQ presented a low cytotoxicity when in vitro assays were performed. Therefore, the
ﬁndings suggest a major role for DIPDHAQ in multiple sclerosis, disease characterized as an autoimmune
inﬂammatory disorder against myelin proteins of the brain and spinal cord. The attenuation of inﬂamma-
tion and consequently improvement of clinical signs, involving a decrease of pro-inﬂammatory cytokines
and the low cytotoxicity of DIPDHAQ, suggest that this compound could be used as an alternative treat-
ment for autoimmune diseases in the central nervous system.
© 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Multiple Sclerosis (MS) is an autoimmune inﬂammatory disease
directed against myelin proteins and is the most common human de-
myelinating disease of the central nervous system (CNS) [1]. It was
demonstrated that the loss of myelin proteins leads to loss of sensi-
tivity, muscle weakness, difﬁculties with coordination, balance, blad-
der and bowel that are standard hallmarks of the pathology [2,3]. A
large number of cytokines and chemokines play pivotal role in the
establishment and maintenance of autoimmune disorders [4]. In the
present study, the experimental autoimmune encephalomyelitis
(EAE) model was used because it resembles many features of MS
such as T-cell mediated autoinﬂammation in the CNS [5].
It has been demonstrated that the anticancer agent mitoxantrone
(MIT), which is an anthracene-based molecule, was efﬁcient in
treating MS and its actions are believed to be due to nonspeciﬁc inhi-
bition of T cell and B cell proliferation and macrophage activation [6].
MIT was ﬁrst tried in the EAEmodel in the mid-1980s, successfully re-
versing paralysis and reducing the number and extent of perivascular
lesions in brain [7]. Clinical development of mitoxantrone was taken
forward in the clinic, leading to its approval for use in MS. In 2000
the FDA approved its use in secondary progressiveMS and progressive.
vier OA license.or worsening relapsing–remitting MS. The treatment with MIT nor-
mally causesmyelosuppression and, depending on the total cumulative
dose, several side effects can be observed, moreover, recent studies
question the efﬁcacy of mitoxantrone and the safety in long-term treat-
ments [7,8]. Therefore, there is a need to develop effective and less toxic
drugs, with speciﬁc effectiveness in reducing the action of autoreactive
immune cells.
In this study, treatment with the anthraquinone derivative O,O′-
bis-(3′-iodopropyl)-1,4-dihidroxyanthraquinone (DIPDHAQ), a mito-
xantrone analog, improved the clinical signs of MOG-induced EAE.
These improvements were associated with reduction of inﬂammatory
cytokines in the spinal cord. Overall, the results indicate DIPDHAQ as a
new candidate compound for the treatment of MS.
2. Materials and methods
2.1. Chemical compounds
Mitoxantrone (MIT) was kindly provided by “Quiral Química
do Brasil S.A.”. The compound O,O′-bis-(3′-chloropropyl)-1,4-
dihidroxyanthraquinone (compound 1) was prepared by treat-
ment of the 1,4-dihidroxyanthraquinone (DHAQ, ACROS) with
potassium carbonate and 1-bromo-3-chloropropane, in butanone
under reﬂux. Reaction of compound 1 with sodium iodide in
butanone at reﬂux furnished DIPDHAQ (Fig. 1). DIPDHAQ was
Table 1
Clinical score assessment.
Part of the body Clinical signs Scorea
Tail No clinical signs 0
Loss of muscle tone in tail 1
Paralysis 2
Hind-limb No clinical signs 0
Weakness of one animal paw 1
Weakness of both animal paws 2
Paralysis of one animal paw 3
Paralysis of both animal paws 4
Front-limb No clinical signs 0
Weakness of any animal paw 1
Paralysis of any animal paw 2
Bladder Continence 0
Incontinence 1
a Numerical score arbitrarily established.
Fig. 1. Chemical structures. (DHAQ, ACROS) 1,4-Dihidroxyanthraquinone, (compound 1) O,O′-bis-(3′-chloropropyl)-1,4-dihidroxyanthraquinone, (DIPDHAQ) O,O′-bis-(3′-iodopropyl)-
1,4-dihidroxyanthraquinone.
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red and NMR spectroscopy.
2.2. In vitro assay
J774A.1 cells weremaintained in RPMI-1640 supplemented (2mM
L-glutamine, 100μg.ml−1 of streptomycin and penicillin, 5% fetal bo-
vine serum) at 37°C in a humidiﬁed atmosphere of 5% CO2. Peritoneal
macrophages of naïve mice were isolated by intraperitoneal injection
of 2.0ml of sterile 3% thioglycollate (Sigma Chemical Co., Saint Louis,
USA). After 3days, mice were sacriﬁced; the peritoneal cavity was
rinsed with 5ml ice-cold PBS containing 0.1% BSA and 20μmol/l di-
sodium EDTA. Cell viability by trypan blue exclusion was >95%.
Cells were seeded in 96-well plates at a density of 1×106 cells/ml.
Cells were incubated at 37°C in 5% CO2 in the presence of mitoxantrone
or DIPDHAQ (25, 5, 1 and 0.2μg/ml) for 48h. Mitoxantrone and its an-
alog DIPDHAQ were solubilized in dimethyl sulfoxide (DMSO — Sigma
St. Louis, MO, USA), never exceeding 0.1% (v/v), and diluted in
RPMI-1640 (Gibco, Grand Island, USA) before use.
2.3. MTT assay
Cell viability was measured using the 3-(4,5-dimethylthiazolyl-2)-
2,5-diphenyltetrazolium bromide (MTT) test in non-stimulated cell
cultures. After 48h of culture the supernatant was removed and the
cells were incubated with 100μl of supplemented RPMI medium
and 10μl of MTT (5mg⁄ml) for 4h at 37°C in 5% CO. The reaction
was stopped by adding to each well 100μl of an acidic isopropanol so-
lution (100ml of isopropyl alcohol⁄0.4ml of HCl 10N). Following
10min of incubation at room temperature, the optical density (OD)
values at 570nm were determined (Spectramax 190; Molecular De-
vices, Sunnyvale, CA, USA) [9,10].
2.4. Animals
Female C57Bl/6 mice 6–8weeks old were obtained from the Ani-
mal Care Facilities of the Federal University of Juiz de Fora (UFJF)
and housed in microisolator cages at the Laboratory of Immunology.
All procedures were in accordance with the principles of the Brazilian
Code for the Use of Laboratory Animals. This project was approved by
the Ethics Committee on the use of laboratory animals from UFJF.
2.5. EAE induction and DIPDHAQ treatment
Groups of 10 mice were subcutaneously (s.c.) immunized or not at
both sides of the tail base with 100μg of MOG35–55 peptide (Sigma)
emulsiﬁed vol/vol in complete Freund's adjuvant (CFA) (Sigma) sup-
plemented with 400μg of attenuated Mycobacterium tuberculosis
H37RA (Difco, Detroit, USA). Pertussis toxin, 300ng/animal (Sigma),
was injected intraperitoneally (i.p.) on the day of immunization and
48h later. Non-immunized mice were used as control.
Immunized mice were divided into three groups (n=10 mice
per group): immunized not-treated (EAE group), immunized andtreated with DIPDHAQ (DIPDHAQ group) and immunized and treated
with Mitoxantrone (MIT group). The EAE group received only vehicle
i.p., DIPDHAQ group or MIT group received 1mg/kg body weight of
DIPDHAQ or mitoxantrone, respectively, in 0.1% DMSO i.p. daily for
7days since the 14th day post-immunization [11].
2.6. Clinical assessment
Mice were weighed and observed daily for clinical signs of EAE up
to 21dpi. The clinical status was assessed scoring certain parts of the
mice body individually according to Table 1 [12,13]. In case of death,
mice were scored 15. The ﬁnal daily clinical score was obtained
adding all individual scores assessed.
2.7. Cytokine and chemokines production in the spinal cord
Spinal cord tissue samples were obtained from control and
immunized mice at day 21 post-immunization and weighted.
One hundred milligrams of tissues was homogenized in 1ml of
0.4M NaCl, 0.05% Tween 20 (Merck & Co., Inc., Whitehouse
Station, USA), containing 0.5% bovine serum albumin (BSA),
0.1M phenylmethylsulfonyl ﬂuoride (PMSF), 0.1M benzethonium
chloride, 10mM ethylenediaminetetraacetic acid (EDTA) and 20
kIU/ml aprotinin (Sigma). The supernatants were collected to de-
termine the concentration of IL-17, IFN-γ, IL-12p40, IL-6, TGF-β,
CCL20 and CCL5 at 1:10 dilution in 1% BSA in phosphate buffered
saline (PBS). Concentrations were assayed by ELISA using com-
mercially available antibodies and according to the procedures
supplied by the manufacturer (BD Biosciences Pharmingen, San
Diego, USA).
2.8. Preparation of spinal cord and histological staining
To evaluate spinal cord tissue histology, ﬁve mice per group were
euthanized under anesthesia perfused by intracardiac puncture with
5ml of 4% buffered formalin on day 21 post-immunization. The spinal
Fig. 2. Cytotoxicity assay. Primary mice peritoneal macrophages (pattern bars) and
J774A.1 cells (plain bars) were cultured by 48hs in the presence of serial dilutions of
MIT and DIPDHAQ (25μg/ml to 0.2μg/ml). Cells were collected to determine the per-
centage of cytotoxicity by the MTT test. Each bar represents the arithmetic mean±
SEM. *, pb0.05 when compared to control (not treated cells). Control cells (0μg/ml),
peritoneal macrophages (pattern bar) and J774A.1 cells (white bar). Results are repre-
sentative of three different experiments.
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8-μm-thick sections were stained with hematoxylin and eosin (H&E)
or 10-μm-thick sections were stained with Luxol fast blue (LFB)–cresyl
violet, to assess tissue damage, inﬂammation and demyelination.2.9. Statistics
Results presented here represent three independent experiments
and are presented as the mean±SEM. The signiﬁcance of differences
between groupswas analyzed using a Student's t-test, Mann–Whitney
test, or two-way ANOVA (GraphPad Prism 5.00) when appropriate.
The differences were considered signiﬁcant at pb0.05.3. Results
3.1. DIPDHAQ treatment showed lower cytotoxicity on macrophages
Cytotoxicity was evaluated as cellular viability in the presence of
various concentrations of the tested compounds. DIPDHAQ did not
present cytotoxic effect in almost all concentrations tested; reducing
the viability to ~50% only in the highest concentration used (25μg/ml)
in J774A.1 macrophage lineage and in mice peritoneal macrophagesFig. 3. Clinical assessment. Animals were monitored daily for clinical signs of EAE after immu
1mg/kg body weight of DIPDHAQ or MIT during 7days. (A) Clinical scores of EAE mice treate
DIPDHAQ. Each point represents the arithmetic mean±SEM. Dashed line: beginning of the(Fig. 2). However, mitoxantrone was cytotoxic at all concentrations
tested, demonstrating the lower toxicity of DIPDHAQ (Fig. 2).
3.2. Neurological deﬁcits
The axonal damage in mice suffering from EAE is represented by
well deﬁned signs such as tail paralysis and hind-limb weakness
[11,12]. Fig. 3A shows that immunized mice presented EAE signs
such as weakness/paralysis of tail and limbs, which became apparent
around days 10–12 following immunization. Moreover, intraperito-
neal injections of DIPDHAQ and MIT demonstrated to be effective in
treating MOG35–55-EAE-induced mice. Clinical signs of disease in
the treated groups showed a minor peak at day 16 after immuniza-
tion (MIT: 2.3±1.02; DIPDHAQ: 2.2±1.03) maintaining lower clini-
cal score, while the untreated group peaked at day 19 (3.8±0.58),
with an elevated clinical score. From the day 17, the group treated
with DIPDHAQ showed pronounced differences in clinical score
(pb0.05) in comparison with the EAE group (Fig. 3A). The injec-
tions of neither DIPDHAQ nor MIT inﬂuenced mean weight com-
pared to non-immunized control or EAE (Fig. 3B).
3.3. Histological evaluation
Spinal cord inﬂammation and demyelination (Fig. 4A) were per-
formed at 21st day post-immunization. Mice from the DIPDHAQ
group presented reduced inﬂammation and demyelination when
compared to EAE group (Fig. 4A). Spinal cord of EAE group showed in-
ﬂammatory cell inﬁltrates in the leptomeningeal siteswhen compared
to negative control (Fig. 4A). Inﬂammatory cell inﬁltrates were associ-
ated to vacuolation and secondary degeneration of parenchyma, con-
sistent with demyelination (Fig. 4A).
3.4. Spinal cord chemokine analyses
CCL20 and CCL5 levels in supernatants frommacerates of spinal cord
were measured at day 21 post-immunization (Fig. 4B and C). The EAE
group showed higher chemokine levels (Fig. 4B and C) when compared
to non-immunized control group (pb0.05). The group treated with
DIPDHAQ showed signiﬁcant (pb0.05) lower levels in comparison
with the EAE group (Fig. 4B and C). MIT treatment increased CCL5
(Fig. 4B).
3.5. Spinal cord cytokine analyses
IL-17, IFN-γ, IL-12p40, IL-6 and TGF-β levels in supernatants of
spinal cord macerates were measured at day 21 post-immunization.
The EAE group showed increased levels of IL-17, IFN-γ, IL-12p40
and IL-6 (Fig. 5A–D) when compared to the non-immunized controlnization with 100μg MOG35–55 peptide. Mice were treated (n=10) or not (n=10) with
d or not with MIT or DIPDHAQ. (B) Mean weight of EAE mice treated or not with MIT or
treatment. *, pb0.05.
Fig. 4. Disease parameters. At 21dpi spinal cords were removed, ﬁxed and embedded in parafﬁn. (A) Histology of spinal cord, H&E and LFB. EAE group showed inﬂammatory sites
(arrows) and secondary degeneration of parenchyma with demyelination. Bar=50μm. (B,C) Chemokine level. Spinal cords were removed and homogenized in an extraction so-
lution (100mg of tissue per 1ml). Supernatants were collected to determine the concentration of CCL5 (B) and CCL20 (C). Each bar represents the arithmetic mean±SEM.
*, pb0.05. Results are representative of three different experiments.
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IFN-γ, IL-12p40, IL-6 and TGF-β (Fig. 5A to E) in comparison with
the EAE group (pb0.05). Surprisingly, only IL-17 and IL-12p40 were
signiﬁcantly decreased in mice treated with MIT (Fig. 5A and D) in
comparison with the EAE group.
4. Discussion
The present study demonstrated that treatmentwith the anthraqui-
none derivative O,O′-bis-(3′-iodopropyl)-1,4-dihidroxyanthraquinone
(DIPDHAQ), improved clinical signs of MOG-induced EAE in C57Bl/6
mice. Amelioration of EAE was associated with lower levels of inﬂam-
matory cytokines in the spinal cord. DIPDHAQhad reduced in vitro cyto-
toxicity in comparison with mitoxantrone (MIT).
MIT is recommended as a ﬁrst line drug for patients with malignant
forms of MS and as a second line drug in those with relapsing-remitting
MS and the secondary progressive MS [14,15]. Although data on long-
term efﬁcacy and safety of MIT in MS patients and the real mechanism
of MIT action are still unknown, recent studies suggested that disease
remission is well maintained in treated patients [7]. Moreover, it is
believed that nonspeciﬁc cytotoxicity effects on macrophages and lym-
phocytes, are the major mechanisms responsible for the clinical effects
of MIT inMS patients [11]. The present study showed high in vitro cyto-
toxicity of MIT on macrophages which could be related with the re-
duced clinical score of the MIT treated mice. In the search for analogs
with optimal therapeutic efﬁcacy, the primary structural changes intro-
duced into the anthracene-9,10-dione have been (a) variation of the
alkylamino side chain and (b) repositioning of the hydroxy substituents
and/or the alkylamino side chains of the anthracenedione chromophore
[16]. The elevated cytotoxicity of mitoxantrone could be related to the
presence of the N–O–O triangulation, which increases DNA binding
potency [17]. Moreover, the reduced cytotoxicity of DIPDHAQ could
be related to the absence of 5,8 hydroxyl groups in the aromatic ring.Different studies related the presence of these groups to cytotoxicity
and notably the cardiotoxicity of mitoxantrone [16–19]. The concentra-
tion of 25μg/ml in the in vitro tests was used to determine a parameter
between MIT and DIPDHAQ in higher doses. Treatment with higher
doses of MIT normally shows plasma values [20] lower than 25μg/ml,
the concentration used in this study, which diminishes the signiﬁcance
of the DIPDHAQ cytotoxic parameter result.
The results presented here indicate that treatment with DIPDHAQ
improves the clinical score of EAE. This improvement was correlated
with lower levels of CCL5, CCL20, IL-17, IFN-γ, IL-12p40, IL-6 and
TGF-β in the spinal cord and with both less inﬂammation and less
demyelination.
The migration of leukocytes to the CNS is orchestrated by
chemokines produced by endothelial cells, perivascular macrophages,
astrocytes, and microglia [21]. It has been demonstrated that the
blockade of CCR6, a CCL20 receptor, inhibited the development of
EAE due to reduced priming of autoreactive CD4+ T cells [22]. The re-
duced levels of CCL5 and CCL20 at the spinal cord in the present work
could be related with reduced recruitment of IFN-γ-producing CD4
cells (CCL5) and IL-17-producing CD4 cells (CCL20), which could ex-
plain the reduced inﬂammatory cell inﬁltrate, and the lower demye-
lination in the DIPDHAQ treated group, causing improvement in
clinical signs.
Demyelination in EAE, such as in MS, is a result of the inﬂammato-
ry lesions in the white matter leading to clinical deﬁcits [23]. The
treatment with DIPDHAQ reduced the demyelination in spinal cord
suggesting a correlation with the lower clinical signs.
IL-17 and IFN-γ play important roles in the induction and severity
of MS and EAE [24,25]. Moreover, the deﬁciency of IL-17 or the use of
IL-17-blocking antibodies prevented the development and/or re-
duced the severity of EAE [24]. IFN-γ is also involved in the induction
and severity of EAE but recent studies showed that IFN-γ secreting
cells inﬁltrate the brain during the development of EAE, but these
Fig. 5. Cytokine level. At 21dpi spinal cords were removed and homogenized in an extraction solution (100mg of tissue per 1ml). Supernatants were collected to determine the
concentration of IL-17 (A), IFN-γ (B), IL-6 (C), IL-12p40 (D), and TGF-β (E). Each bar represents the arithmetic mean±SEM. *, pb0.05. Results are representative of three different
experiments.
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follows the onset of clinical symptoms [25,26]. Furthermore, it has
been suggested that EAE can be induced by transferring T cells that
secrete IL-17, but not by T cells that secrete IFN-γ, although both
types of cells can cross the blood–brain barrier and inﬁltrate the
CNS [27]. Therefore, based in the results presented here, the above
pathway seems to be correlated with DIPDHAQ effects, leading to a
decreased inﬂammation and reduction of EAE signs.
IL-12 has also been considered important in EAE, where studies of
IL-12 subunits (IL-12p35 and IL-12p40) revealed that p40−/− mice
were resistant to EAE development, whereas p35−/−mice were sus-
ceptible to EAE [28,29]. Considering that IL-12p40 subunit is also part
of IL-23, special attention was given to IL-23 in EAE, and it is believed
that p40−/−mice were resistant to EAE as a result of decreased IL-23
activity and point to a minor role of IL-12 for EAE development [30].
In accordance, the present study has demonstrated a reduction in
IL-12p40 levels after DIPDHAQ treatment, which could be associated
with lower number of IL-17 producing cells and improved clinical
score.
IL-6 is known to be involved in CNS inﬂammation and pathology of
EAE, either directly through activation of microglia and astrocytes [31]
or indirectly, together with TGF-β, by promoting the differentiation
and expansion of Th17 cells [32]. In the present work DIPDHAQ treat-
ment decreased the levels of IL-6 and TGF-β, which could have affected
IL-17 production.In conclusion, treatment with DIPDHAQ (O,O′-bis-(3′-iodopropyl)-
1,4-dihidroxyanthraquinone) showed to be effective in improving the
clinical signs of EAE, which appears to be associated with lower levels
of CCL5, CCL20, IFN-γ and IL-17 in the spinal cord. The role played by
CCL5 and CCL20 in modulating IFN-γ and IL-17 production and amelio-
rating EAE and MS deserves further attention.Acknowledgments
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